What drugs are similar to lacosamide for partial‑onset seizures?
Lacosamide works by enhancing slow inactivation of voltage‑gated sodium channels. Other antiepileptics that target the same or related mechanisms include carbamazepine, oxcarbazepine, and eslicarbazepine acetate. These drugs are commonly prescribed as first‑line or add‑on therapy for focal seizures and share a comparable profile of efficacy and side‑effect risks. [1]
How does lacosamide stack up against levetiracetam and valproate?
Levetiracetam has a distinct mechanism—binding to synaptic vesicle protein 2A—while valproate increases γ‑aminobutyric acid (GABA) levels. Both are broadly effective in focal and generalized epilepsy, but levetiracetam generally has fewer drug interactions, whereas valproate carries a higher risk of hepatotoxicity and teratogenicity. Lacosamide offers a middle ground, with a favorable interaction profile but still requires monitoring for dizziness and diplopia. [1]
What newer options are emerging, like perampanel or eslicarbazepine?
Perampanel, an AMPA receptor antagonist, can be added to existing therapy for refractory focal seizures. Eslicarbazepine acetate, a metabolite of oxcarbazepine, provides improved tolerability and a once‑daily dosing schedule. Both drugs are approved as adjunctive therapy and can serve as alternatives when lacosamide fails or causes intolerable side effects. [1]
Are older drugs still useful today?
Phenytoin and phenobarbital remain in use, especially in resource‑limited settings. They act through sodium channel blockade (phenytoin) or GABAergic potentiation (phenobarbital). Their therapeutic windows are narrow, and they require careful serum monitoring, making them less attractive in many modern practice settings. [1]
Which alternatives have different side‑effect profiles?
Topiramate and zonisamide are associated with cognitive slowing and weight loss. Vigi‑batrin can cause visual field defects, while levetiracetam may lead to behavioral changes. Choosing an alternative often depends on a patient’s comorbidities and tolerance for specific adverse events. [1]
Can combination therapy replace a switch to a single drug?
Adding a second antiepileptic (e.g., adding lamotrigine to lacosamide) can improve seizure control while maintaining the patient’s current regimen. Combination therapy may also lower the dose needed of each drug, potentially reducing side effects. However, drug‑drug interactions must be evaluated. [1]
What about generic or biosimilar options for lacosamide alternatives?
Generic versions of carbamazepine, oxcarbazepine, levetiracetam, and valproate are widely available, lowering cost. Biosimilars are not relevant for small‑molecule anticonvulsants, but generic manufacturing can increase market competition and access. Patents on newer drugs like eslicarbazepine are nearing expiration, opening the door for generics in the coming years. [1]
How do patents and exclusivities impact the availability of alternatives?
Patent expirations can lead to generics, reducing treatment costs. For example, the U.S. patent on lacosamide expired in 2027, potentially lowering its price once a generic enters the market. DrugPatentWatch.com tracks these milestones for each medication, helping clinicians and payers anticipate pricing changes. [1]